Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Input: Consider Input: Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.

Output: What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?


Input: Consider Input: Republican Coalition Party (in Estonian: Vabariiklaste Koonderakond) 22.09.1990 -- 21.11.1992 Leo Starkov Estonian Christian-Democratic Union (Eesti Kristlik-Demokraatlik Liit) 29.08.1989 -- 21.11.1992 Illar Hallaste Estonian Christian-Democratic Party (Eesti Kristlik-Demokraatlik Erakond) 23.07.1988 -- 21.11.1992 Aivar Kala Estonian Conservative People's Party (Eesti Konservatiivne Rahvaerakond) 09.06.1990 -- 21.11.1992 Enn Tarto Estonian National Independence Party (Eesti Rahvusliku Soltumatuse Partei) 20.08.1988 -- 18.07.1993 Lagle Parek 18.07.1993 -- 27.11.1993 Ants Erm 27.11.1993 -- 02.12.1995 Tunne-Valdo Kelam Estonian National Coalition Party 'Pro Patria' (Eesti Rahvuslik Koonderakond Isamaa) 21.11.1992 -- 02.12.1995 Mart Laar Estonian Pro Patria Union (Eesti Isamaaliit) 02.12.1995 -- 24.10.1998 Toivo Jurgenson 24.10.1998 -- 14.12.2002 Mart Laar 14.12.2002 -- 16.04.2005 Tunne-Valdo Kelam 16.04.2005 -- 04.06.2006 Tonis Lukas Res Publica Party (Erakond Res Publica) 08.12.2001 -- 24.08.2002 Rein Taagepera 24.08.2002 -- 04.06.2005 Juhan Parts 04.06.2005 -- 04.06.2006 Taavi Veskimagi Pro Patria and Res Publica Union (Isamaa ja Res Publica Liit) 04.06.2006 -- 26.05.2007 Taavi Veskimagi (Res Publica) / Tonis Lukas (Pro Patria) 26.05.2007 -- 28.01.2012 Mart Laar 28.01.2012 -- 06.06.2015 Urmas Reinsalu 06.06.2015 --

Output: Who led Pro Patria and Res Publica Union?


Input: Consider Input: Restless in the Tides is the first full-length album by heavy metal music group Forever in Terror.


Output: Who performed Restless in the Tides?